Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up.
Acquired cervical dystonia
Botulinum toxin A
Efficacy
Long-term outcome
Safety
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
30
05
2022
accepted:
17
08
2022
revised:
09
08
2022
pubmed:
7
9
2022
medline:
7
1
2023
entrez:
6
9
2022
Statut:
ppublish
Résumé
Botulinum toxin A (BoNT/A) is the first-line treatment for idiopathic cervical dystonia (ICD) and is widely used in the clinical setting. To date, scanty data are available on the effectiveness of BoNT in treating acquired cervical dystonia (ACD). Here we present a long-term follow-up of ACD patients treated with BoNT/A that focused on safety and efficacy. The study included subjects who had received at least six treatments of three commercially available BoNT/A drugs [abobotulinumtoxinA (A/Abo), incobotulinumtoxinA (A/Inco) and onabotulinumtoxinA (A/Ona)]. Safety and efficacy were assessed based on patients' self-reports regarding adverse effects (AE), duration of improvement of dystonia and/or pain relief. Global clinical improvement was measured on a six-point scale. 23 patients with ACD were administered 739 treatments (A/Abo in 235, A/Inco in 72, A/Ona in 432) with a mean number of treatments of 31 ± 20 (range 6-76) and duration of 10 ± 6 weeks (range 2-25). The mean dose was 737 ± 292 U for A/Abo, 138 ± 108 U for A/Inco and 158 ± 80 U for A/Ona. The average benefit duration was 89 ± 26 (A/Abo), 88 ± 30 days (A/Inco), and 99 ± 55 days (A/Ona) (p = 0.011); global clinical improvement for all sessions was 4 ± 1. ANOVA one-way analysis indicated that A/Ona had the best profile in terms of duration (p < 0.05), whereas A/Abo had the best pain relief effect (p = 0.002). Side effects were reported in 9% of treatments (67/739), with ten treatments (1%) complicated by two side effects. Most side effects were rated mild to moderate; severe side effects occurred following three treatments with the three different BoNT; two required medical intervention. No allergic reactions were reported. Even after 25 years of repeated treatments, all serotypes of BoNT demonstrate positive effects in treating ACD with long-lasting efficacy and safety.
Identifiants
pubmed: 36068376
doi: 10.1007/s00415-022-11343-0
pii: 10.1007/s00415-022-11343-0
pmc: PMC9813057
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
340-347Informations de copyright
© 2022. The Author(s).
Références
Ercoli T et al (2021) Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. Parkinson Relat Disord 87:70–74. https://doi.org/10.1016/j.parkreldis.2021.04.022
doi: 10.1016/j.parkreldis.2021.04.022
Albanese A et al (2013) Phenomenology and classification of dystonia: a consensus update. Mov Disord Off J Mov Disord Soc 28(7):863–873. https://doi.org/10.1002/mds.25475
doi: 10.1002/mds.25475
Finsterer J, Maeztu C, Revuelta GJ, Reichel G, Truong D (2015) Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J Neurol Sci 355(1–2):37–43. https://doi.org/10.1016/j.jns.2015.06.015
doi: 10.1016/j.jns.2015.06.015
Mainka T, Erro R, Rothwell J, Kühn AA, Bhatia KP, Ganos C (2019) Remission in dystonia—systematic review of the literature and meta-analysis. Parkinson Relat Disord 66:9–15. https://doi.org/10.1016/j.parkreldis.2019.02.020
doi: 10.1016/j.parkreldis.2019.02.020
Rodrigues FB et al (2020) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 11:CD003633. https://doi.org/10.1002/14651858.CD003633.pub4
doi: 10.1002/14651858.CD003633.pub4
Yahalom G, Fay-Karmon T, Livneh V, Israeli-Korn S, Ephraty L, Hassin-Baer S (2021) Botulinum injections for idiopathic cervical dystonia: a longitudinal study. Neurotox Res 39(4):1352–1359. https://doi.org/10.1007/s12640-021-00378-2
doi: 10.1007/s12640-021-00378-2
Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265–273. https://doi.org/10.1007/s12640-012-9314-y
doi: 10.1007/s12640-012-9314-y
Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo-Fermo S, Albanese A (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 15(3):224–231. https://doi.org/10.1007/s12640-009-9023-3
doi: 10.1007/s12640-009-9023-3
Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo-Fermo S, Albanese A (2009) Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol 16(3):392–398. https://doi.org/10.1111/j.1468-1331.2008.02507.x
doi: 10.1111/j.1468-1331.2008.02507.x
Jinnah HA (2020) Medical and surgical treatments for dystonia. Neurol Clin 38(2):325–348. https://doi.org/10.1016/j.ncl.2020.01.003
doi: 10.1016/j.ncl.2020.01.003
Factor SA, Friedman JH (1997) The emerging role of clozapine in the treatment of movement disorders. Mov Disord Off J Mov Disord Soc 12(4):483–496. https://doi.org/10.1002/mds.870120403
doi: 10.1002/mds.870120403
van den Heuvel CNAM, Tijssen MAJ, van de Warrenburg BPC, Delnooz CCS (2016) The symptomatic treatment of acquired dystonia: a systematic review. Mov Disord Clin Pract 3(6):548–558. https://doi.org/10.1002/mdc3.12400
doi: 10.1002/mdc3.12400
Brashear A, Ambrosius WT, Eckert GJ, Siemers ER (1998) Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord Off J Mov Disord Soc 13(1):158–161. https://doi.org/10.1002/mds.870130130
doi: 10.1002/mds.870130130
Jochim A et al (2019) Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. J Neurol 266(8):1879–1886. https://doi.org/10.1007/s00415-019-09349-2
doi: 10.1007/s00415-019-09349-2
Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord Off J Mov Disord Soc 21(10):1737–1741. https://doi.org/10.1002/mds.21051
doi: 10.1002/mds.21051
Castagna A, Albanese A (2019) Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance. Neurol Clin Pract 9(1):64–73. https://doi.org/10.1212/CPJ.0000000000000568
doi: 10.1212/CPJ.0000000000000568
Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A (2012) Retrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 33(2):261–267. https://doi.org/10.1007/s10072-011-0672-7
doi: 10.1007/s10072-011-0672-7
Vivancos-Matellano F, Ybot-Gorrin I, Diez-Tejedor E (2012) A 17-year experience of abobotulinumtoxina in cervical dystonia. Int J Neurosci 122(7):354–357. https://doi.org/10.3109/00207454.2012.665971
doi: 10.3109/00207454.2012.665971
Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord Off J Mov Disord Soc 20(5):592–597. https://doi.org/10.1002/mds.20376
doi: 10.1002/mds.20376
Hsiung G-YR, Das SK, Ranawaya R, Lafontaine A-L, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord Off J Mov Disord Soc 17(6):1288–1293. https://doi.org/10.1002/mds.10252
doi: 10.1002/mds.10252
Ramirez-Castaneda J, Jankovic J (2014) Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon Off J Int Soc Toxinol 90:344–348. https://doi.org/10.1016/j.toxicon.2014.07.009
doi: 10.1016/j.toxicon.2014.07.009
Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord Off J Mov Disord Soc 19(3):303–308. https://doi.org/10.1002/mds.10659
doi: 10.1002/mds.10659
Patterson A et al (2016) Occurrence of dysphagia following botulinum toxin injection in parkinsonism-related cervical dystonia: a retrospective study. Tremor Hyperkinetic Mov N Y N 6:379. https://doi.org/10.7916/D8GB24C5
doi: 10.7916/D8GB24C5
Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis». Curr Med Res Opin 20(7):981–990. https://doi.org/10.1185/030079904125003962
doi: 10.1185/030079904125003962
Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A (2013) Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry 84(9):1014–1019. https://doi.org/10.1136/jnnp-2012-303608
doi: 10.1136/jnnp-2012-303608
Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31(5):463–466. https://doi.org/10.1179/174313209X405137
doi: 10.1179/174313209X405137
Jankovic J (2004) Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75(7):951–957. https://doi.org/10.1136/jnnp.2003.034702
doi: 10.1136/jnnp.2003.034702
Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) CD-017 BoNTA Study Group, Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord Off J Mov Disord Soc 23(10):1353–1360. https://doi.org/10.1002/mds.22157
doi: 10.1002/mds.22157
Jankovic J et al (2015) Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 349(1–2):84–93. https://doi.org/10.1016/j.jns.2014.12.030
doi: 10.1016/j.jns.2014.12.030
Misra VP, Trosch RM, Maisonobe P, Om S (2018) Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies. J Clin Mov Disord 5:4. https://doi.org/10.1186/s40734-018-0072-8
doi: 10.1186/s40734-018-0072-8
Moll M, Rosenthal D, Hefter H (2018) Quality of life in long-term botulinum toxin treatment of cervical dystonia: results of a cross sectional study. Parkinsonism Relat Disord 57:63–67. https://doi.org/10.1016/j.parkreldis.2018.07.019
doi: 10.1016/j.parkreldis.2018.07.019
Dressler D (2011) Nonprimary dystonias. Handb Clin Neurol 100:513–538. https://doi.org/10.1016/B978-0-444-52014-2.00038-0
doi: 10.1016/B978-0-444-52014-2.00038-0
Painous C et al (2020) Management of rare movement disorders in Europe: outcome of surveys of the European reference network for rare neurological diseases. Eur J Neurol 27(8):1493–1500. https://doi.org/10.1111/ene.14302
doi: 10.1111/ene.14302
Camargo CHF, Teive HAG, Becker N, Munhoz RP, Werneck LC (2011) Botulinum toxin type A and cervical dystonia: a seven-year follow-up. Arq Neuropsiquiatr 69(5):745–750. https://doi.org/10.1590/s0004-282x2011000600004
doi: 10.1590/s0004-282x2011000600004
Godeiro-Júnior C, Felício AC, Aguiar PC, Borges V, Silva SMA, Ferraz HB (2009) Neuroleptic-induced tardive cervical dystonia: clinical series of 20 patients. Can J Neurol Sci J Can Sci Neurol 36(2):222–226. https://doi.org/10.1017/s0317167100006582
doi: 10.1017/s0317167100006582
Kang UJ, Burke RE, Fahn S (1986) Natural history and treatment of tardive dystonia. Mov Disord Off J Mov Disord Soc 1(3):193–208. https://doi.org/10.1002/mds.870010305
doi: 10.1002/mds.870010305
Molho ES, Feustel PJ, Factor SA (1998) Clinical comparison of tardive and idiopathic cervical dystonia. Mov Disord Off J Mov Disord Soc 13(3):486–489. https://doi.org/10.1002/mds.870130319
doi: 10.1002/mds.870130319
Strader S, Rodnitzky RL, Gonzalez-Alegre P (2011) Secondary dystonia in a botulinum toxin clinic: clinical characteristics, neuroanatomical substrate and comparison with idiopathic dystonia. Parkinson Relat Disord 17(10):749–752. https://doi.org/10.1016/j.parkreldis.2011.07.013
doi: 10.1016/j.parkreldis.2011.07.013
Bentivoglio AR et al (2017) Long-term abobotulinumtoxin A treatment of cervical dystonia. Neurotox Res 32(2):291–300. https://doi.org/10.1007/s12640-017-9737-6
doi: 10.1007/s12640-017-9737-6
Flynn TC (2010) Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol 11(3):183–199. https://doi.org/10.2165/11530110-000000000-00000
doi: 10.2165/11530110-000000000-00000